Addressing Performance, Scalability, and Regulatory Challenges to Accelerate Cell Therapy Manufacturing: To date, the FDA has approved 36 cell and gene therapy products (1). In the past decade, new cell therapy modalities such as chimeric antigen receptor T-cell (CAR-T) immunotherapies have emerged as promising treatments especially for many types of cancers. There are now six FDA approved commercially available CAR-T products (2) and the development of cell therapies is continuing to gather pac

• Published in: Biopharm international Vol. 37; no. 7; p. 14
• Main Authors: Cashen, Paul, Deckers, Susanne, Ladi, Rukmini
• Format: Magazine Article
• Language: English
• Published: Intellisphere, LLC 01.07.2024
• Subjects: Antigens; Drug approval; Gene therapy; Genes; Immunotherapy; T cells